LEVINE WEIGHS IN ON PRECISION MEDICINE RAPIDLY BEING INCORPORATED INTO OVARIAN CANCER CARE
Memorial Sloan Kettering Cancer Center
PRGs
Douglas Levine, MD, director of the Division of Gynecologic Oncology at Perlmutter Cancer Center, NYU Langone School of Medicine, sat down with OncLive at ASCO to provide his insight on precision medicine, explaining how it is a particular benefit in ovarian cancer. Using the method is especially useful for clinical trial enrollment and in determining whether patients are eligible to receive treatment with PARP inhibitors.